SOST
Sclerostin
As of the edition of 20 October 2026, SOST (sclerostin, UniProt Q9BQB4) has 3 drugs tested at it and 4 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9BQB4
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 3
- Disease areas
- Bones, joints and muscles; Nutrition and metabolism; Skin and connective tissue; Inherited and neonatal; Injuries; Nervous system; Cancer; Blood and lymph
- Registered trials of its drugs
- 53
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Romosozumab | Marketed | Phase 4 | Ends 2031 |
| Setrusumab | Active | Phase 3 | none listed |
| Blosozumab | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Engaged | 1 |
| Total on the list | 4 |
The other 1 company at SOST
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at SOST, ranked, with the facts behind eachRequest access. Nothing is shown until you do.